Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-b
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma
01:02am, Tuesday, 14'th Apr 2026
IDEAYA Biosciences (NASDAQ: IDYA) shared top-line results from its randomized phase II/III OptimUM-02 study evaluating darovasertib in combination with crizotinib as a frontline treatment for HLA-A2 n
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
07:48am, Monday, 13'th Apr 2026
IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
07:21am, Monday, 13'th Apr 2026
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30,
SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pr
Ideaya Biosciences: Key Pivotal Data Imminent
05:04am, Wednesday, 08'th Apr 2026
Ideaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melanoma candidate. IDYA maintains a strong cash runway of 3–4 years, supporting a robust and expanding
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)
01:25am, Tuesday, 07'th Apr 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) was the target of unusually large options trading on Monday. Stock investors acquired 24,287 call options on the stock. This represents an inc
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,0
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 27'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $48.69
01:31am, Saturday, 21'st Mar 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the firm, Marketbe
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
06:00am, Wednesday, 18'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for thr
